Skip to main content
SpringerLink
Log in

Apixaban zur Therapie und Rezidivprophylaxe venöser Thromboembolien im Juli 2014 zugelassen

  • Kurz notiert
  • Published:
MMW - Fortschritte der Medizin Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Pressegespräch „Breites Indikationsspektrum für Apixaban (Eliquis®) — jetzt auch zugelassen zur Behandlung und Rezidivprophylaxe venöser Thromboembolien“; Frankfurt am Main, September 2014 (Veranstalter: BMS und Pfizer)

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Red

Authors
  1. Red
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Red Apixaban zur Therapie und Rezidivprophylaxe venöser Thromboembolien im Juli 2014 zugelassen. MMW - Fortschritte der Medizin 156 (Suppl 6), 96 (2014). https://doi.org/10.1007/s15006-014-3699-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-014-3699-x

Search

Navigation